Rituximab-including combined modality treatment for primary thyroid lymphoma: An effective regimen for elderly patients

Natsuko Watanabe, Hiroto Narimatsu, Jaeduk Yoshimura Noh, Yo Kunii, Koji Mukasa, Masako Matsumoto, Miho Suzuki, Kenichi Sekiya, Hidemi Ohye, Ai Yoshihara, Kenji Iwaku, Sachiko Kobayashi, Kaori Kameyama, Kazuhiko Kobayashi, Yoshitaka Nishikawa, Masahiro Kami, Kiminori Sugino, Koichi Ito

研究成果: Article査読

11 被引用数 (Scopus)

抄録

Background: Primary thyroid lymphoma (PTL) develops mostly in middle-aged and older females. However, the optimal treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL), which accounts for most PTL cases, is unclear. Rituximab is a promising drug that, in combination with traditional combination therapy, has demonstrated an increased antitumor effect without a substantial increase in toxicity. In this study, treatment outcomes of elderly patients with thyroid DLBCL who underwent rituximab-including combination therapy were analyzed. Method: Between January 2005 and December 2011, 43 patients 60 years of age or older (median 71 years, range 60-80 years) were diagnosed as having stage IE (n = 12) or stage IIE (n = 31) DLBCL, and three courses of R-CHOP therapy (rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, adriamycin 40 mg/m2, vincristine 1.4 mg/m 2, and prednisolone 100 mg/body) and involved field irradiation were planned. Treatment outcomes of these patients were retrospectively reviewed. Results: Two patients terminated the treatment because of interstitial pneumonia during R-CHOP therapy. Only one patient showed treatment resistance and the regimen was changed; 42 patients (98%) responded to the treatment. Five-year overall survival and event-free survival were 87% (95% confidence interval [95% CI], 64-96%) and 74% (95% CI, 50-89%), respectively. Conclusion: The results of the present study indicate that rituximab-including combination therapy was effective for elderly patients with thyroid DLBCL. A multicenter, long-term observational study is needed to confirm this, and additional refinement of the treatment protocol is required to optimize the antitumor effect.

本文言語English
ページ(範囲)994-999
ページ数6
ジャーナルThyroid
24
6
DOI
出版ステータスPublished - 2014 6月 1
外部発表はい

ASJC Scopus subject areas

  • 内分泌学、糖尿病および代謝内科学
  • 内分泌学

フィンガープリント

「Rituximab-including combined modality treatment for primary thyroid lymphoma: An effective regimen for elderly patients」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル